Welcome to our dedicated page for Solid Bioscience news (Ticker: SLDB), a resource for investors and traders seeking the latest updates and insights on Solid Bioscience stock.
Solid Biosciences Inc. (SLDB) is a precision genetic medicine company whose news flow centers on the development of gene therapy candidates for rare neuromuscular and cardiac diseases. Company announcements highlight progress across multiple clinical programs, regulatory designations and collaborations related to its investigational therapies and platform technologies.
Investors and observers following SLDB news can expect updates on key clinical trials such as INSPIRE DUCHENNE and IMPACT DUCHENNE for SGT-003 in Duchenne muscular dystrophy, the FALCON Phase 1b trial of SGT-212 in Friedreich’s ataxia, and the ARTEMIS Phase 1b trial of SGT-501 for catecholaminergic polymorphic ventricular tachycardia. News items also describe interim clinical data, including safety, tolerability, biomarker changes and cardiac monitoring findings, as well as regulatory interactions and designations from agencies such as the U.S. Food and Drug Administration and U.K. authorities.
Solid Biosciences’ news releases additionally cover its proprietary AAV-SLB101 capsid platform, including data presentations at scientific meetings and licensing agreements with partners such as Andelyn Biosciences. Corporate updates, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in industry conferences like the J.P. Morgan Healthcare Conference also appear in the company’s news record.
This news page aggregates these disclosures so readers can review clinical milestones, regulatory developments, platform collaborations and corporate events related to Solid Biosciences and its SLDB stock over time.
Solid Biosciences (Nasdaq: SLDB) announced that Dr. Carl Morris, Chief Scientific Officer, will participate in a panel discussion on Duchenne muscular dystrophy (DMD) at the virtual Guggenheim Healthcare Talks on April 1, 2021, from 9:00 a.m. to 9:50 a.m. EDT. The panel, titled “The more we learn the less we know about DMD,” will explore advancements in DMD therapies. A live webcast of the event will be available on the company’s investor relations website, with a replay accessible afterward.
Solid Biosciences (Nasdaq: SLDB) announced the closing of an underwritten public offering of 25 million shares of common stock at $5.75 each, generating approximately $143.8 million in gross proceeds. This offering included 3.26 million shares from the underwriters' option to purchase additional shares. Jefferies, SVB Leerink, and Piper Sandler were the joint book-running managers for the offering. The shares were issued under an effective shelf registration statement, filed with the SEC on March 13, 2019, and declared effective on March 19, 2019.
Solid Biosciences (Nasdaq: SLDB) has announced the pricing of an underwritten public offering of 21,739,131 shares at $5.75 per share, generating total gross proceeds of $125 million before expenses. An option allows underwriters to purchase an additional 3,260,869 shares. The offering is expected to close on March 23, 2021, subject to customary conditions. Proceeds will fund research and development for SGT-001 and other corporate purposes. The offering involves an effective registration statement filed with the SEC.
Solid Biosciences announced a public offering of $85 million in common stock to enhance funding for its Duchenne muscular dystrophy therapies. The offering is underwritten and includes a 30-day option for underwriters to purchase an additional 15%. Jefferies, SVB Leerink, and Piper Sandler are managing the offering, which is subject to market conditions. The shares are offered under an effective registration statement filed with the SEC. No assurance can be given regarding the offering's completion or its terms due to market uncertainties.
Solid Biosciences Inc. (Nasdaq: SLDB) has reported promising interim data from its IGNITE DMD Phase I/II trial of SGT-001, a gene therapy for Duchenne muscular dystrophy. Data from six patients indicate improvements in functional endpoints, including scores from the North Star Ambulatory Assessment and the 6-Minute Walk Test, with some patients showing a mean improvement in walking distance by over 37 meters. Recent dosing of a seventh patient was successful, with manageable side effects. The next steps involve continued enrollment and evaluation of additional patient outcomes.
Solid Biosciences (Nasdaq: SLDB) announced the grant of an inducement award to its new Chief Legal Officer, Erin Brennan, as approved by independent directors on February 25, 2021. The inducement award consists of an option to purchase 325,000 shares of common stock at an exercise price of $8.52 per share, with a ten-year term and vesting in four equal annual installments. This appointment aims to strengthen the company's leadership in developing therapies for Duchenne muscular dystrophy.
Solid Biosciences (Nasdaq: SLDB) announces key leadership changes aimed at advancing therapies for Duchenne muscular dystrophy. Erin Powers Brennan joins as Chief Legal Officer, while Joel Schneider is promoted to Chief Operating Officer. The company also expands its Board of Directors with the appointments of Clare Kahn and Georgia Keresty, both experienced in the healthcare and pharmaceutical sectors. These moves are expected to enhance the company's strategic direction and operational capabilities in developing its lead gene therapy candidate, SGT-001, and improving patient outcomes.
Solid Biosciences (Nasdaq: SLDB) announced the presentation of one-year efficacy and safety data from the ongoing IGNITE-DMD Phase I/II study of SGT-001 microdystrophin gene therapy for Duchenne muscular dystrophy. Principal Investigator Dr. Barry Byrne will present the findings at the 2021 MDA Virtual Clinical & Scientific Conference on March 18 at 4 PM ET. Additionally, a symposium on Real World Outcomes Measures will take place on the same day. A conference call discussing interim data and financial results is scheduled for March 15 at 4:30 PM ET.
Solid Biosciences (Nasdaq: SLDB) has announced participation in two upcoming investor conferences. Chief Technology Officer Joel Schneider and Acting Chief Medical Officer Cathryn Clary will present at the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 1:40 p.m. ET, and at the Barclays Global Healthcare Conference on March 11, 2021, at 9:45 a.m. ET. Live webcasts will be available on the company’s investor relations website, with replays also accessible afterwards. Solid Biosciences aims to develop therapies for Duchenne muscular dystrophy through its lead gene therapy candidate, SGT-001.
Solid Biosciences, a life sciences company focused on therapies for Duchenne muscular dystrophy, announced that CEO Ilan Ganot will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 8:20 am ET. Following the presentation, leadership will be available for Q&A. Institutional investors interested in meetings can contact their J.P. Morgan representative. A live webcast will be accessible on the company's website, with a replay available for 30 days.